share_log

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 Second Quarter Results

Walgreens Boots Alliance | 8-K: Current report

沃爾格林-聯合博姿 | 8-K:重大事件
美股sec公告 ·  03/28 07:19
Moomoo AI 已提取核心訊息
On March 28, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending February 29, 2024. The company experienced a second-quarter loss per share of $6.85, primarily due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Despite this, adjusted earnings per share (EPS) rose by 3.4% to $1.20, attributed to a lower adjusted effective tax rate and improved U.S. Healthcare profitability. Quarterly sales increased by 6.3% year-over-year to $37.1 billion. WBA narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, citing a challenging U.S. retail environment and other factors, while maintaining its U.S. Healthcare adjusted EBITDA guidance. The company's CEO, Tim Wentworth, expressed optimism about U.S. Healthcare's positive adjusted EBITDA and the company's execution in pharmacy services. WBA also announced a strategic portfolio review over the next three months to drive growth and deliver value.
On March 28, 2024, Walgreens Boots Alliance, Inc. (WBA) reported its financial results for the fiscal quarter ending February 29, 2024. The company experienced a second-quarter loss per share of $6.85, primarily due to a $5.8 billion after-tax non-cash impairment charge related to VillageMD goodwill. Despite this, adjusted earnings per share (EPS) rose by 3.4% to $1.20, attributed to a lower adjusted effective tax rate and improved U.S. Healthcare profitability. Quarterly sales increased by 6.3% year-over-year to $37.1 billion. WBA narrowed its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, citing a challenging U.S. retail environment and other factors, while maintaining its U.S. Healthcare adjusted EBITDA guidance. The company's CEO, Tim Wentworth, expressed optimism about U.S. Healthcare's positive adjusted EBITDA and the company's execution in pharmacy services. WBA also announced a strategic portfolio review over the next three months to drive growth and deliver value.
2024年3月28日,Walgreens Boots Alliance, Inc.(WBA)公佈了截至2024年2月29日的財季財務業績。該公司第二季度每股虧損6.85美元,這主要是由於與VillageMD商譽相關的58億美元稅後非現金減值費用。儘管如此,調整後的每股收益(EPS)增長了3.4%,至1.20美元,這要歸因於調整後的有效稅率降低和美國醫療保健盈利能力的提高。季度銷售額同比增長6.3%,達到371億美元。WBA以美國零售環境艱難和其他因素爲由,將2024財年調整後的每股收益預期縮小至3.20美元至3.35美元,同時維持其經美國醫療保健調整後的息稅折舊攤銷前利潤指引。該公司首席執行官蒂姆·溫特沃斯對美國醫療保健調整後的息稅折舊攤銷前利潤和該公司在藥房服務方面的執行表示樂觀。WBA還宣佈了未來三個月的戰略投資組合審查,以推動增長並創造價值。
2024年3月28日,Walgreens Boots Alliance, Inc.(WBA)公佈了截至2024年2月29日的財季財務業績。該公司第二季度每股虧損6.85美元,這主要是由於與VillageMD商譽相關的58億美元稅後非現金減值費用。儘管如此,調整後的每股收益(EPS)增長了3.4%,至1.20美元,這要歸因於調整後的有效稅率降低和美國醫療保健盈利能力的提高。季度銷售額同比增長6.3%,達到371億美元。WBA以美國零售環境艱難和其他因素爲由,將2024財年調整後的每股收益預期縮小至3.20美元至3.35美元,同時維持其經美國醫療保健調整後的息稅折舊攤銷前利潤指引。該公司首席執行官蒂姆·溫特沃斯對美國醫療保健調整後的息稅折舊攤銷前利潤和該公司在藥房服務方面的執行表示樂觀。WBA還宣佈了未來三個月的戰略投資組合審查,以推動增長並創造價值。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息